Principia Biopharma Inc (NASDAQ:PRNB) – Analysts at Svb Leerink issued their Q1 2019 earnings estimates for Principia Biopharma in a research note issued on Thursday, March 21st. Svb Leerink analyst G. Porges forecasts that the company will post earnings of ($0.46) per share for the quarter. Svb Leerink also issued estimates for Principia Biopharma’s Q2 2019 earnings at ($0.58) EPS, FY2019 earnings at ($2.28) EPS, FY2020 earnings at ($3.39) EPS, FY2021 earnings at ($2.43) EPS and FY2022 earnings at ($4.69) EPS.

Several other analysts have also recently commented on the company. Zacks Investment Research cut Principia Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. Leerink Swann set a $42.00 price target on Principia Biopharma and gave the company a “buy” rating in a report on Thursday, March 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $42.00.

PRNB opened at $33.92 on Monday. The company has a market capitalization of $805.94 million and a PE ratio of 59.51. Principia Biopharma has a 12 month low of $22.00 and a 12 month high of $38.34.

Principia Biopharma (NASDAQ:PRNB) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.68. The business had revenue of $26.14 million during the quarter, compared to analyst estimates of $13.70 million.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in Principia Biopharma in the 4th quarter valued at approximately $41,000. Citigroup Inc. purchased a new position in Principia Biopharma in the 4th quarter valued at approximately $45,000. American International Group Inc. purchased a new position in Principia Biopharma in the 4th quarter valued at approximately $103,000. Citadel Advisors LLC purchased a new position in Principia Biopharma in the 3rd quarter valued at approximately $211,000. Finally, Victory Capital Management Inc. purchased a new position in Principia Biopharma in the 3rd quarter valued at approximately $234,000. 81.91% of the stock is owned by hedge funds and other institutional investors.

About Principia Biopharma

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

Recommended Story: What is the QQQ ETF?

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.